Geron Corporation GERN shares have risen 40% so far this year against the industry’s decrease of 3%, riding on the progress of its sole pipeline candidate, imetelstat.
Imetelstat is being evaluated as a treatment for hematologic myeloid malignancies like myelofibrosis (“MF”) in a phase II IMbark study and myelodysplastic syndromes (“MDS”) in a phase II/III IMerge study.
Notably, both the studies are being conducted by Geron, following the termination of the collaboration related to imetelstat development by Johnson & Johnson JNJ last year. The candidate enjoys orphan drug designation for both the indications.
Geron is progressing well with the development of imetelstat. In May, the company completed the transfer of the sponsorship of the investigational new drug related to imetelstat from Janssen. Geron now holds the full responsibility for the development of imetelstat.
Enrollment has been stopped in the phase II portion of IMerge study and the company anticipates top-line data from it by the end of 2019. Preliminary data presented last year had shown that the benefit/risk profile of imetelstat in treated patients, including the expansion arm, supports continued development in lower risk MDS indication. Based on this data, the company initiated the phase III portion of the IMerge study earlier this month.
Geron has also added new leaders to its development team with vast experience in oncology and drug development to support the progress of imetelstat.
Meanwhile, the company postponed the date of the end of phase II meeting related to IMbark study to the first quarter of 2020 from the third quarter of this year. The extended period is likely to be used for further analysis of data from the IMbark study, which may support the regulatory application seeking approval of imetelstat in relapsed/refractory MF.
Although the company’s operating expense is set to increase due to cost of imetelstat development following the termination of collaboration with J&J, Geron has sufficient funds to start the phase III portion of IMerge studies.
However, dependence on a single pipeline candidate is a concern. Any hiccups in development of imetelstat may hurt Geron’s stock significantly. Meanwhile, Acceleron Pharma XLRN and its partner Celgene’s CELG luspatercept, which is being developed for MDS in a phase III study, may give competition to imetelstat.
Geron Corporation Price
Geron Corporation price | Geron Corporation Quote
Geron currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Johnson & Johnson (JNJ) : Free Stock Analysis Report
Celgene Corporation (CELG) : Free Stock Analysis Report
Acceleron Pharma Inc. (XLRN) : Free Stock Analysis Report
Geron Corporation (GERN) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research